BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38256120)

  • 1. Folate Receptor Alpha-A Novel Approach to Cancer Therapy.
    Gonzalez T; Muminovic M; Nano O; Vulfovich M
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting the folate receptor α in oncology.
    Scaranti M; Cojocaru E; Banerjee S; Banerji U
    Nat Rev Clin Oncol; 2020 Jun; 17(6):349-359. PubMed ID: 32152484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies targeting folate receptor α for ovarian cancer.
    Mai J; Wu L; Yang L; Sun T; Liu X; Yin R; Jiang Y; Li J; Li Q
    Front Immunol; 2023; 14():1254532. PubMed ID: 37711615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The folate receptor as a rational therapeutic target for personalized cancer treatment.
    Assaraf YG; Leamon CP; Reddy JA
    Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in using folate receptor 1 (FOLR1) for cancer diagnosis and treatment, with an emphasis on cancers that affect women.
    Varaganti P; Buddolla V; Lakshmi BA; Kim YJ
    Life Sci; 2023 Aug; 326():121802. PubMed ID: 37244363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
    Nunez MI; Behrens C; Woods DM; Lin H; Suraokar M; Kadara H; Hofstetter W; Kalhor N; Lee JJ; Franklin W; Stewart DJ; Wistuba II
    J Thorac Oncol; 2012 May; 7(5):833-40. PubMed ID: 22729036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate Receptor α-Targeted
    Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
    Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Martin LP; Konner JA; Moore KN; Seward SM; Matulonis UA; Perez RP; Su Y; Berkenblit A; Ruiz-Soto R; Birrer MJ
    Gynecol Oncol; 2017 Nov; 147(2):402-407. PubMed ID: 28843653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
    Gonzalez-Ochoa E; Veneziani AC; Oza AM
    Clin Med Insights Oncol; 2023; 17():11795549231187264. PubMed ID: 37528890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
    Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
    Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gilbert L; Oaknin A; Matulonis UA; Mantia-Smaldone GM; Lim PC; Castro CM; Provencher D; Memarzadeh S; Method M; Wang J; Moore KN; O'Malley DM
    Gynecol Oncol; 2023 Mar; 170():241-247. PubMed ID: 36736157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer.
    Chu W; Zhou Y; Tang Q; Wang M; Ji Y; Yan J; Yin D; Zhang S; Lu H; Shen J
    Biosci Trends; 2018 Jul; 12(3):298-308. PubMed ID: 29899195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
    Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
    Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farletuzumab in lung cancer.
    Thomas A; Maltzman J; Hassan R
    Lung Cancer; 2013 Apr; 80(1):15-8. PubMed ID: 23357463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?
    Kelemen LE
    Int J Cancer; 2006 Jul; 119(2):243-50. PubMed ID: 16453285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro.
    Kamen BA; Smith AK
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):113-20. PubMed ID: 22644798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid.
    Péraudeau E; Cronier L; Monvoisin A; Poinot P; Mergault C; Guilhot F; Tranoy-Opalinski I; Renoux B; Papot S; Clarhaut J
    J Control Release; 2018 Jan; 269():36-44. PubMed ID: 29129656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid mediates activation of the pro-oncogene STAT3 via the Folate Receptor alpha.
    Hansen MF; Greibe E; Skovbjerg S; Rohde S; Kristensen AC; Jensen TR; Stentoft C; Kjær KH; Kronborg CS; Martensen PM
    Cell Signal; 2015 Jul; 27(7):1356-68. PubMed ID: 25841994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
    Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.